Can Basilea’s Antibiotic Succeed Where Others Have Failed?

Company Looks To Partner Ceftobiprole Ahead Of US Approval

The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.

Basilea announced Phase III results in serious Staphylococcus aureus infections • Source: Shutterstock

Basilea Pharmaceutica Ltd. unveiled positive Phase III results for ceftobiprole in Staphylococcus aureus bacteremia (SAB), on top of existing Phase III data for the drug in acute bacterial skin and skin structure infection (ABSSSI). The company is looking to partner the product for the US market and hoping that differentiation from existing treatments can help it succeed where other new anti-infectives have failed.

The Phase III ERADICATE trial compared intravenous ceftobiprole against intravenous daptomycin with or without aztreonam in 390 patients with complicated SAB, including right-side endocarditis. The Swiss biotech already had positive results from the Phase III TARGET trial in 679 patients with ABSSSI, which completed in 2019. Based on the results of the two trials, the company plans to file for US Food and Drug Administration approval of ceftobiprole around the end of 2022

More from Strategy

More from Business

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By 

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.